Israel Englander Achilles Therapeutics PLC Transaction History

Millennium Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.82 - $1.57 $9,702 - $18,576	-11,832 Reduced 38.23%	19,117 $23,000
Q4 2023 Feb 14, 2024	SELL	$0.78 - $0.96 $5,787 - $7,123	-7,420 Reduced 19.34%	30,949 $27,000
Q2 2023 Aug 14, 2023	SELL	$0.82 - $1.09 $72,881 - $96,879	-88,880 Reduced 69.85%	38,369 $36,000
Q1 2023 May 15, 2023	BUY	$0.84 - $1.26 $38,214 - $57,322	45,494 Added 55.65%	127,249 $122,000
Q4 2022 Feb 14, 2023	BUY	$0.79 - $2.39 $64,586 - $195,394	81,755 New	81,755 $74,000

24.3M

Ticker ACHL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,774,000
Market Cap $47.3M
Description
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.